Jagdeep Shur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jagdeep Shur has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Robert Price
University of Bath
3 shared publications Chonladda Pitchayajittipong
Pharmaceutical Surface Science Research Group, Department of Pharmacy & Pharmacology, University of Bath, Bath, BA2 7AY, UK
2 shared publicationsJ. Sebastian Kaerger
Aeropharm GmbH, Rudolstadt, Germany
1 shared publication- Lindsay J. Marshall
Humane Society International, The Humane Society of the United States, 700 Professional Drive, Gaithersburg, MD 20879, USA
1 shared publication Philippe Rogueda
Faculty of Pharmacy & Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville VIC 3052, Australia
1 shared publication- Stephen Edge
Pharmaceutical Technology Research Group, Department of Pharmacy and Pharmacology, University of Bath, Bath, UK
1 shared publication
Latest Publications
- 1 December 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 514 (2) , 399-406
Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin
- 1 December 2016
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 514 (2) , 399-406
Investigation of the enhanced antimicrobial activity of combination dry powder inhaler formulations of lactoferrin
- 1 August 2013
- Published by Future Science Ltd in Therapeutic Delivery
- Vol. 4 (8) , 925-937
Effect of processing history on the surface interfacial properties of budesonide in carrier-based dry-powder inhalers
Influence of air-jet micronization, post-micronization conditioning and storage on the surface properties of budesonide in dry-powder inhaler formulations was investigated. Crystalline budesonide was air jet-micronized and conditioned using organic vapor. Particle engineering was also used to fabricate respirable particles of budesonide. Surface imaging by atomic force microscopy suggested that micronized material possessed process-induced surface disorder, which relaxed upon conditioning with organic vapor. Particle engineered material was devoid of such surface disorder. Surface interfacial properties of all batches were different and correlated to in vitro fine particle delivery. The surface properties and in vitro performance of the conditioned material changed upon storage of the budesonide at 44% relative humidity and 25°C, while the micronized and particle-engineered material remained stable. These data suggest that processing conditions of budesonide affected the surface properties of the material, which was demonstrated to have direct affect on dry-powder inhaler formulation performance.
- 1 August 2013
- Published by Future Science Ltd in Therapeutic Delivery
- Vol. 4 (8) , 925-937
Effect of processing history on the surface interfacial properties of budesonide in carrier-based dry-powder inhalers
Influence of air-jet micronization, post-micronization conditioning and storage on the surface properties of budesonide in dry-powder inhaler formulations was investigated. Crystalline budesonide was air jet-micronized and conditioned using organic vapor. Particle engineering was also used to fabricate respirable particles of budesonide. Surface imaging by atomic force microscopy suggested that micronized material possessed process-induced surface disorder, which relaxed upon conditioning with organic vapor. Particle engineered material was devoid of such surface disorder. Surface interfacial properties of all batches were different and correlated to in vitro fine particle delivery. The surface properties and in vitro performance of the conditioned material changed upon storage of the budesonide at 44% relative humidity and 25°C, while the micronized and particle-engineered material remained stable. These data suggest that processing conditions of budesonide affected the surface properties of the material, which was demonstrated to have direct affect on dry-powder inhaler formulation performance.
- 10 May 2010
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 390 (2) , 134-141
Characterisation and functionality of inhalation anhydrous lactose
- 10 May 2010
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 390 (2) , 134-141
Characterisation and functionality of inhalation anhydrous lactose